A biomarker study for atezolizumab in patients with relapsed/refractory NK/T-cell lymphoma (ATTACK)
Not Applicable
- Conditions
- extranodal NK/T-cell lymphoma, nasal type (ENKL)
- Registration Number
- JPRN-UMIN000039968
- Lead Sponsor
- ational Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Gene alterations by targeted DNA sequence 2. Gene expression and fusion genes by targeted RNA sequence 3. Positive rate of PD-1, PD-L1, and PD-L2 by histopathological evaluation
- Secondary Outcome Measures
Name Time Method 1. Gene alterations and expressions by whole exome, whole genome, and RNA sequence 2. Gene expressions, TCR/BCR repertoires, surface markers, and antigen specificity by ingle cell analysis 3. Gene and surface marker expressions using preserved peripheral blood samples